Participant global assessment: satisfaction with treatment ‐ inframammary Questionnaire · participants with hidradenitis suppurativa
Intense pulsed light showed no clear difference in participant global assessment: satisfaction with treatment ‐… compared with no treatment (low certainty).
1 finding from 1 review
RR 3 [0.24, 37.67]
1 study · 2 participants
Low
Modified HS‐LASI score after 3 months · participants with hidradenitis suppurativa
1 finding from 1 review
Modified HS‐LASI score after 3 months ‐ axilla · participants with hidradenitis suppurativa
1 finding from 1 review
Modified HS‐LASI score after 3 months ‐ groin · participants with hidradenitis suppurativa
1 finding from 1 review
Modified HS‐LASI score after 3 months ‐ inframammary · participants with hidradenitis suppurativa
1 finding from 1 review
no estimate extracted
1 study · 8 participants
Very low
Percentage change in modified HS‐LASI score after 5 months compared with baseline · participants with hidradenitis suppurativa
1 finding from 1 review
Percentage change in modified HS‐LASI score after 5 months compared with baseline ‐ axilla · participants with hidradenitis suppurativa
1 finding from 1 review
Percentage change in modified HS‐LASI score after 5 months compared with baseline ‐ groin · participants with hidradenitis suppurativa
1 finding from 1 review
Treatment discontinuation · participants with hidradenitis suppurativa
Adalimumab weekly showed no clear difference in frequency of treatment discontinuation compared with placebo (moderate certainty).
1 finding from 1 review
HS‐LASI score · participants with hidradenitis suppurativa
1 finding from 1 review
Physician Global Assessment (Thongprasom score) · participants with hidradenitis suppurativa
Staphage lysate probably leads to higher physician global assessment compared with placebo broth (moderate certainty).
1 finding from 1 review
Proportion of participants with infectious adverse effects · participants with hidradenitis suppurativa
Adalimumab weekly showed no clear difference in proportion of participants with infectious adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
Proportion with improvement in pain VAS · participants with hidradenitis suppurativa
Adalimumab weekly probably leads to higher proportion with improvement in pain VAS compared with placebo (moderate certainty).
1 finding from 1 review
Change in modified Sartorius scale score (imputation) · participants with hidradenitis suppurativa
1 finding from 1 review
Change in DLQI score (LOCF) · participants with hidradenitis suppurativa
1 finding from 1 review
Frequency of serious adverse effects · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in frequency of serious adverse effects compared with placebo (high certainty).
1 finding from 1 review
Incidence of herpes labialis after use of the preventative intervention · participants with recurrent herpes labialis
Oral aciclovir (short‐term) showed no clear difference in incidence of herpes labialis during use of the preventative… compared with placebo (moderate certainty).
1 finding from 1 review
Adherence · participants with recurrent herpes labialis
1 finding from 1 review
Incidence of herpes labialis after use of the preventative intervention · participants with recurrent herpes labialis
Valaciclovir (short‐term) showed no clear difference in incidence of HSL during use of the preventative intervention (by… compared with placebo (moderate certainty).
1 finding from 1 review
Incidence of HSL during use of the preventative intervention (by culture) · participants with recurrent herpes labialis
Valaciclovir (short‐term) showed no clear difference in incidence of HSL during use of the preventative intervention (by… compared with placebo (moderate certainty).
1 finding from 1 review